Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: Implications for cancer therapy

Current Cancer Drug Targets

Volumn 12, Issue 2, 2012, Pages 124-131

  Cejas, P ^a   Lopez Gomez M ^b   Aguayo, C ^a   Madero, R ^a   Moreno Rubio, J ^a   de Castro Carpeno J ^a   Belda Iniesta, C ^a   Barriuso, J ^a   Moreno Garcia V ^a   Diaz E ^a   Burgos, E ^a   Gonzalez Baron M ^a   Feliu, J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

Anti EGFR therapy; BRAF; Colorectal cancer; KRAS; Metastasis; PIK3CA; PTEN

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; CANCER THERAPY; COLORECTAL CANCER; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRAS GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATIONAL ANALYSIS; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84856452707     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912799095162     Document Type: Article

References (31)

1. Saltz, L. B.; Meropol, N. J.; Loehrer, P. J. Sr.; Needle, M. N.; Kopit, J.; Mayer, R. J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208.
2. Chung, K. Y.; Shia, J.; Kemeny, N. E.; Shah, M.; Schwartz, G. K.; Tse, A.; Hamilton, A.; Pan, D.; Schrag, D.; Schwartz, L.; Klimstra, D. S.; Fridman, D.; Kelsen, D. P.; Saltz, L. B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005, 23, 1803-1810.
3. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351, 337-345.
4. Saltz, L. Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? Clin. Colorectal Cancer 2005, 5, S98-100.
5. Lièvre, A.; Bachet, J. B.; Le Corre, D.; Boige, V.; Landi, B.; Emile, J. F.; Côté, J. F.; Tomasic, G.; Penna, C.; Ducreux, M.; Rougier, P.; Penault-Llorca, F.; Laurent-Puig, P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66, 3992-3995.
6. Amado, R. G.; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D. J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R.; Patterson, S. D.; Chang, D. D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 1626-1634.
7. Karapetis, C. S.; Khambata-Ford, S.; Jonker, D. J.; O'Callaghan, C. J.; Tu, D.; Tebbutt, N. C.; Simes, R. J.; Chalchal, H.; Shapiro, J. D.; Robitaille, S.; Price, T. J.; Shepherd, L.; Au, H. J.; Langer, C.; Moore, M. J.; Zalcberg, J. R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359, 1757-1765.
8. Di Nicolantonio, F.; Martini, M.; Molinari, F.; Sartore-Bianchi, A.; Arena, S.; Saletti, P.; De Dosso, S.; Mazzucchelli, L.; Frattini, M.; Siena, S.; Bardelli, A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 5705-5712.
9. Loupakis, F.; Ruzzo, A.; Cremolini, C.; Vincenzi, B.; Salvatore, L.; Santini, D.; Masi, G.; Stasi, I.; Canestrari, E.; Rulli, E.; Floriani, I.; Bencardino, K.; Galluccio, N.; Catalano, V.; Tonini, G.; Magnani, M.; Fontanini, G.; Basolo, F.; Falcone, A.; Graziano, F. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 2009, 4, 715-721.
10. Laurent-Puig, P.; Cayre, A.; Manceau, G.; Buc, E.; Bachet, J. B.; Lecomte, T.; Rougier, P.; Lievre, A.; Landi, B.; Boige, V.; Ducreux, M.; Ychou, M.; Bibeau, F.; Bouché, O.; Reid, J.; Stone, S.; Penault-Llorca, F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 2009, 27, 5924-5930.
11. Sartore-Bianchi, A.; Martini, M.; Molinari, F.; Veronese, S.; Nichelatti, M.; Artale, S.; Di Nicolantonio, F.; Saletti, P.; De Dosso, S.; Mazzucchelli, L.; Frattini, M.; Siena, S.; Bardelli, A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009, 69, 1851-1857.
12. Perrone, F.; Lampis, A.; Orsenigo, M.; Di Bartolomeo, M.; Gevorgyan, A.; Losa, M.; Frattini, M.; Riva, C.; Andreola, S.; Bajetta, E.; Bertario, L.; Leo, E.; Pierotti, M. A.; Pilotti, S. PIK3CA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 2009, 20, 84-90.
13. Sartore-Bianchi, A.; Di Nicolantonio, F.; Nichelatti, M.; Molinari, F.; De Dosso, S.; Saletti, P.; Martini, M.; Cipani, T.; Marrapese, G.; Mazzucchelli, L.; Lamba, S.; Veronese, S.; Frattini, M.; Bardelli, A.; Siena, S. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4, e7287.
14. Prenen, H.; De Schutter, J.; Jacobs, B.; De Roock, W.; Biesmans, B.; Claes, B.; Lambrechts, D.; Van Cutsem, E.; Tejpar, S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res. 2009, 9, 3184-3188.
15. De Roock, W.; Claes, B.; Bernasconi, D.; De Schutter, J.; Biesmans, B.; Fountzilas, G.; Kalogeras, K. T.; Kotoula, V.; Papamichael, D.; Laurent-Puig, P.; Penault-Llorca, F.; Rougier, P.; Vincenzi, B.; Santini, D.; Tonini, G.; Cappuzzo, F.; Frattini, M.; Molinari, F.; Saletti, P.; De Dosso, S.; Martini, M.; Bardelli, A.; Siena, S.; Sartore-Bianchi, A.; Tabernero, J.; Macarulla, T.; Di Fiore, F.; Gangloff, A.O.; Ciardiello, F.; Pfeiffer, P.; Qvortrup, C.; Hansen, T. P.; Van Cutsem, E.; Piessevaux, H.; Lambrechts, D.; Delorenzi, M.; Tejpar, S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 8, 753-762.
16. Vogelstein, B.; Fearon, E. R.; Hamilton, S. R.; Kern, S. E.; Preisinger, A. C.; Leppert, M.; Nakamura, Y.; White, R.; Smits, A. M.; Bos, J. L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319, 525-532.
17. Etienne-Grimaldi, M. C.; Formento, J. L.; Francoual, M.; François, E.; Formento, P.; Renée, N.; Laurent-Puig, P.; Chazal, M.; Benchimol, D.; Delpero, J. R.; Letoublon, C.; Pezet, D.; Seitz, J. F.; Milano, G. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin. Cancer Res. 2008, 14, 4830-4835.
18. Santini, D.; Loupakis, F.; Vincenzi, B.; Floriani, I.; Stasi, I.; Canestrari, E.; Rulli, E.; Maltese, P. E.; Andreoni, F.; Masi, G.; Graziano, F.; Baldi, G. G.; Salvatore, L.; Russo, A.; Perrone, G.; Tommasino, M. R.; Magnani, M.; Falcone, A.; Tonini, G.; Ruzzo, A. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008, 13, 1270-1275.
19. Cejas, P.; López-Gómez, M.; Aguayo, C.; Madero, R.; de Castro Carpeño, J.; Belda-Iniesta, C.; Barriuso, J.; Moreno García, V.; Larrauri, J.; López, R.; Casado, E.; Gonzalez-Barón, M.; Feliu, J. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. Plos One 2009, 4, e8199.
20. Santini, D.; Spoto, C.; Loupakis, F.; Vincenzi, B.; Silvestris, N.; Cremolini, C.; Canestrari, E.; Graziano, F.; Galluccio, N.; Salvatore, L.; Caraglia, M.; Zito, F. A.; Colucci, G.; Falcone, A.; Tonini, G.; Ruzzo, A. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann. Oncol. 2010, 7, 1565.
21. Loupakis, F.; Pollina, L.; Stasi, I.; Ruzzo, A.; Scartozzi, M.; Santini, D.; Masi, G.; Graziano, F.; Cremolini, C.; Rulli, E.; Canestrari, E.; Funel, N.; Schiavon, G.; Petrini, I.; Magnani, M.; Tonini, G.; Campani, D.; Floriani, I.; Cascinu, S.; Falcone, A. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol. 2009, 27, 2622-2629.
22. Park, J. H.; Han, S. W.; Oh, D. Y.; Im, S. A.; Jeong, S. Y.; Park, K. J.; Kim, T. Y.; Bang, Y. J.; Park, J. G. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother. Pharmacol. 2011, 4, 1045-1055.
23. Scartozzi, M.; Bearzi, I.; Berardi, R.; Mandolesi, A.; Fabris, G.; Cascinu, S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFRtargeted monoclonal antibodies. J. Clin. Oncol. 2004, 22, 4772-4778.
24. Landis, J. R.; Koch, G. G. An application of hierarchical kappatype statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977, 33, 363-374.
25. Molinari, F.; Martin, V.; Saletti, P.; De Dosso, S.; Spitale, A.; Camponovo, A.; Bordoni, A.; Crippa, S.; Mazzucchelli, L.; Frattini, M. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br. J. Cancer 2009, 100, 1087-1094.
26. McKay, J. A.; Murray, L. J.; Curran, S.; Ross, V. G.; Clark, C.; Murray, G. I.; Cassidy, J.; McLeod, H. L. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur. J. Cancer 2002, 38, 2258-2264.
27. Italiano, A.; Follana, P.; Caroli, F.X.; Badetti, J. L.; Benchimol, D.; Garnier, G.; Gugenheim, J.; Haudebourg, J.; Keslair, F.; Lesbats, G.; Lledo, G.; Roussel, J. F.; Pedeutour, F.; François, E. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann. Surg. Oncol. 2008, 15, 649-654.
28. Sawai, H.; Yasuda, A.; Ochi, N.; Ma, J.; Matsuo, Y.; Wakasugi, T.; Takahashi, H.; Funahashi, H.; Sato, M.; Takeyama, H. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol. 2008, 8, 56.
29. Roock, W. D.; Vriendt, V. D.; Normanno, N.; Ciardiello, F.; Tejpar, S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011, 6, 594-603.
30. Van Cutsem, E.; Lang, I.; Folprecht, G.; Van Cutsem, E.; Köhne, C. H.; Láng, I.; Folprecht, G.; Nowacki, M. P.; Cascinu, S.; Shchepotin, I.; Maurel, J.; Cunningham, D.; Tejpar, S.; Schlichting, M.; Zubel, A.; Celik, I.; Rougier, P.; Ciardiello, F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011, 15, 2011-2019.
31. Ogino, S.; Nosho, K.; Kirkner, G. J.; Shima, K.; Irahara, N.; Kure, S.; Chan, A. T.; Engelman, J. A.; Kraft, P.; Cantley, L. C.; Giovannucci, E. L.; Fuchs, C. S. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J. Clin. Oncol. 2009, 9, 1477-1484.